Takeda: 12 NMEs Poised To Launch In Five Years, And Deliver $10 Bn In Peak Sales
The Japanese pharma held its first investor day in New York, outlining the company's strategy to deliver long-term growth through a newly energized oncology, gastrointestinal and rare disease pipeline.
You may also be interested in...
Maribavir is the first antiviral agent targeting and inhibiting the pUL97 protein kinase, as well as Takeda's second new molecular entity approved by FDA this year.
As Takeda pays down debt associated with the acquisition of Shire and advances R&D programs toward global filings, the company is selling its growth plan to investors – but are they buying?
Takeda's acquisition of Shire fueled the company into a top 10 pharma company in the latest Scrip 100 rankings, as other mega-mergers are set to shape the leaderboard in the future.